Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses
Karl L. Banta(Cancer Research Institute), Ira Mellman(Unknown), Chikara Takahashi, Laëtitia Comps‐Agrar(Gene Therapy Laboratory), Xiaozheng Xu(University of California San Diego), Avantika S. Chitre, Amelia Au‐Yeung, William O’Gorman(Genomic Health (United States)), Rafael Cubas(Theravance Biopharma (United States)), Enfu Hui(University of California San Diego), Stephanie Mittman(Translational Research in Oncology), Eric J. Bennett(University of California San Diego), Eugene Y. Chiang(Gene Therapy Laboratory), Jane L. Grogan(Biogen (United States)), Thomas D. Wu
Cited by 362
Related Papers
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
|Science|2017|1.7k
Endocytosis and the recycling of plasma membrane.
|The Journal of Cell Biology|1983|1.5k
The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
|Nature Immunology|2008|1.5k
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
|Clinical Cancer Research|2009|1.4k